Eloqua form Landing

Related Clinical Trials

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage...

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher...

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score

This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating...

Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in high risk HER2-positive patients with residual invasive breast cancer following neoadjuvant therapy

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher...

Testing the usual treatment of radiation therapy and hormonal therapy to hormonal therapy alone for low-risk, early stage breast cancer

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive...

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate...

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation (JANUS)

This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course chemoradiation in patients with stage II-III rectal...

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after...

View All

News

View All

NorthShore – Edward-Elmhurst Hospitals Earn A’s in Leapfrog Hospital Safety Grades Six of NorthShore – Edward-Elmhurst Health’s (NS-EEH) seven eligible hospitals have received an A in the Fall 2023 Hospital Safety Grades from The Leapfrog Group, a national nonprofit watchdog that sets standards for excellence in patient care: Edward Hospital (Naperville), Elmhurst Hospital, NorthShore Evanston Hospital, NorthShore Glenbrook Hospital, NorthShore Highland Park Hospital and Northwest Community Hospital (Arlington Heights). Swedish Hospital (Chicago) earned a B.

If you have reached this screen, your current device or browser is unable to access the full Edward-Elmhurst Health Web site.

To see the full site, please upgrade your browser to the most recent version of Safari, Chrome, Firefox or Internet Explorer. If you cannot upgrade your browser, you can remain on this site.

;

Eloqua form Landing

Newsletter

Sign up for our newsletter

Related Clinical Trials

News